• About
  • Meet The Team
  • Privacy Policy
Saturday, January 16, 2021

Stocks Telegraph
  • Login
  • Home
  • Featured
  • Investing
  • Morning News
  • Mid Day Movers
No Result
View All Result
Stocks Telegraph
No Result
View All Result

Here’s Why You Should Avoid iBio (IBIO) Stocks For COVID-19 Vaccine

by Hasnain R
September 18, 2020
in Featured, Mid Day Movers
Share on FacebookShare on Twitter

All the companies involved in the production of the coronavirus vaccine, iBio is far behind from its competitors in the vaccine trial. The company has earlier revealed that it has selected IBIO-201, its LicKM-ubunit vaccine, as its leading candidate for the prevention of coronavirus infection. But the company has not provided any promising result related to its coronavirus vaccine candidate nor it entered into the human trial of its vaccine candidate.

iBio, a biotech innovator and biologics contract manufacturing organization has earlier made the various claims about its vaccine candidate. It has claimed exclusive worldwide license agreement on a cure called ACE2-Fc from Planet  Biotechnology. Not only this, but the company also claimed that its FastPharming system has the ability to produce vaccines quickly using plant cells.

So, it is better to avoid iBio for the coronavirus vaccine until it catches up and moves its coronavirus vaccine candidate into human trials. Many companies including Moderna, Novavax, AstraZeneca, and Pfizer all are currently in human trials of their vaccine candidate. But iBio, Inc. is still in the lab and far behind from its competitors. To reach the market human trials are necessary.

Shares of iBio, Inc. (IBIO) traded up 9.30% as it gained +0.20 on Thursday. In the past 52-weeks of trading, this company’s stock has fluctuated between the low range of $0.05 and a high range of $7.45. iBio has moved up 4600.00% from its 52-weeks low and moved down -68.46% from its 52-weeks high. Looking at its profitability, its return on assets and investment is -108.70%, and -57.60%, respectively. If we turn our focus on its liquidity, its current ratio is 1.70. iBio, Inc. market capitalization has remained high, hitting $420.46 million at the time of writing.

There are various sciences behind iBio stock. If we look at the political stories, Donald Trump is looking for a vaccine before November. Similarly, from a business point of view, billions were given to the companies for the products which are not ready for the market yet. If we turn our focus on iBio, it only claims that it has a vaccine candidate but that is still in the lab.

It has not advanced it trial to humans which is necessary. iBio stocks soared after it revealed about the FastPharming. But it is not clear yet whether the company has a vaccine or not or it is the trick of the company to excite its stock. So, it is better to avoid the stock of iBio for the coronavirus vaccine until it starts a human trial.

Get The Best Stocks To Trade Every Day!

Join now to get the Stockstelegraph.com pre-market morning brief 100% free

Tags: Coronavirus VaccineIBIOiBio Inc.IBIO StockLicKM-ubunit

Related Posts

Top 15 Information Technology Stocks You Should Be Holding
Featured

Why Momo Inc (MOMO) Is Attracting Investors?

January 14, 2021
Telecom Stocks to Look Out for in 2021
Featured

Telecom Stocks to Look Out for in 2021

January 13, 2021
TG Therapeutics (NASDAQ: TGTX) Ublituximab Receives Fast Track Designation In US
Featured

Why T2 Biosystems Inc. (TTOO) is stock surging in the Pre-market hours today?

January 12, 2021
Top 20 Banking Industry Stocks For October 2020
Featured

Are These The Best Battery Stocks To Buy This Year

January 11, 2021
Blonder Tongue Receives U.S. Patent Grant For DMM Series Of Products
Featured

Can We Expect Growth From General Electric (GE) In 2021?

January 11, 2021
Beasley Broadcast Group (NASDAQ: BBGI) Announces Operating Results
Featured

Where The Li Auto (LI), XPeng (XPEV) Stocks Are Heading To

January 8, 2021
Next Post
Top Stock Performers as Markets Rebound On Improved Jobless Numbers

Two Reasons Why ClearOne Inc [CLRO] is a Perfect Buy at Current Prices

Early Morning Vibes: The 4 Best Stocks To Buy Now

Blonder Tongue Receives U.S. Patent Grant For DMM Series Of Products
by Shan Zee
January 14, 2021
0

American stock markets ended trading largely in the green zone on January 13. The S&P 500 index improved to 3810...

Read more

Early Morning Vibes: Check Out These 4 hot Stocks Right Now

GILT Stock
by Shan Zee
January 12, 2021
0

On January 11, American stock markets closed in the red. The S & P500 index fell 0.66% to 3800 points,...

Read more

Early Morning Vibes: Watch These 4 Stocks Today

Beasley Broadcast Group (NASDAQ: BBGI) Announces Operating Results
by Shan Zee
January 13, 2021
0

The US stock indexes were traded in small ranges on January 12. The S&P 500 has risen symbolically by 0.04%...

Read more

Early Morning Vibes: 4 Stocks We Like for Friday

by Shan Zee
January 15, 2021
0

On January 14, the American stock indices closed in the red. The S&P 500 index dropped 0.38% to 3796 points,...

Read more

Early Morning Vibes: 4 Top Trending Stocks To Watch For Monday

GEVO Inc [GEVO]  – A Top Stock To Watch For The Remainder Of 2020
by Shan Zee
January 11, 2021
0

Last week indices in the United States managed to set fresh records on the price boards. Interestingly, we saw Wall...

Read more
  • About
  • Meet The Team
  • Privacy Policy

© 2020 Stocks Telegraph - All Rights Reserved

No Result
View All Result
  • Home
  • Featured
  • Investing
  • Morning News
  • Mid Day Movers

© 2020 Stocks Telegraph - All Rights Reserved

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Get The Best Stocks To Trade Every Day!

Join now to get the Stockstelegraph.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.